Pfizer eyes four-fold price hike for COVID vaccine in private US market – 21 OCT 2022 – FiercePharma.
- Pfizer revealed during an investor call that it is considering charging a private-market price between $110 and $130 per dose for its COVID shot Comirnaty, which was co-developed by BioNTech.
- The price is not out of line with other vaccines that are provided to adults. It is more than what CVS, for example, charges for a flu shot ($50 or $95), but is less than many other vaccines including Pneumovax 23 ($141), hepatitis ($145), meningitis ($179), shingles ($205) and HPV ($261)
Pfizer lifts revenue outlook as Covid jab price rise boosts sales – 1 NOV 2022 – FT
- US drugmaker’s coronavirus vaccine has almost doubled in price since its launch in 2020
- Pfizer raised its sales forecast for its Covid-19 vaccine by $2bn to $34bn on Tuesday, as higher prices offset a slowdown in demand outside the US.
- The US drugmaker said strong sales of its bivalent booster, which targets the Omicron variant’s dominant strain, and some of its other drugs helped it offset damage from a strong dollar.
- “With regard to our Covid-19 products, while their sales may fall from our expected 2022 levels we believe our Covid-19 franchises will remain multibillion-dollar revenue generators for the foreseeable future, which should serve as a buffer for any unforeseen challenges with other products,” said Albert Bourla, Pfizer chief executive.
- Bourla told analysts on a conference call it was not unreasonable that annual sales of Pfizer’s Covid products — its vaccine Comirnaty and Paxlovid — could be worth about $15bn by 2030. But this would depend on how the virus evolved, he said.